Ista Pharmaceuticals — Investor Presentation (January 2012)
58 slides from Ista Pharmaceuticals's investor presentation, Jan 4, 2012
Slide 1: 2012 Guidance and Pipeline Update
Exhibit 99.2 2012GuidanceandPipelineUpdate January4, 2012
Slide 2: Agenda
Agenda • ISTA’s Track Record of Success – 2011: Solid Commercial and Pipeline Progress – Attractive portfolio of highly valuable assets • ISTA’s Financial Strategy and Outlook – 2012 Guidance – Delivering Value Looking - to 2015 and Beyond • ISTA Exploring Strategic Options • Q&A ISTA PHARMACEUTICAL
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements contained herein are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied
Slide 4: ISTA's Track Record of Success and Strategic Vision
ISTA’s Track Record of Success and Strategic Vision ISTA PHARMACEUTICALS 4
Slide 5: ISTA's Track Record of Success
ISTA’s Track Record of Success • Third largest branded Rx eye care company in U.S. – Thriving core Rx eye business, emerging Rx allergy franchise • 5 Rx eye and allergy product approvals obtained in 6 years – ISTALOL®, VITRASE®, XIBROM™, BEPREVE®, BROMDAY™ • Productsare#1 or #2 in their markets,with
Slide 6: 2011 – Solid Commercial and Pipeline Progress
2011 – Solid Commercial and Pipeline Progress • Preliminary unaudited revenues >$160 million, profitable* • Highly successful switch from XIBROM to BROMDAY • BEPREVE revenue and market share increased significantly • Strong clinical pipeline progress, significant de-risking of programs – PROLENSA™ P
Slide 7: Current Commercial Products
Current Commercial Products $300 Million Near-Term Potential Revenue BROMDAY™ BEPREVE® Only once-daily Fast growing, twice-daily prescription eye drop for prescription eye drop for postoperative inflammation ocular itching associated and reduction of ocular with allergic conjunctivitis pain in patie
Slide 8: Proprietary Bromfenac Franchise High Strategic and Financial Value
Proprietary Bromfenac Franchise High Strategic and Financial Value Portfolio of Assets Delivering Compelling Value Unique Eye Care Franchise • ONLY approved once-daily NSAID BROMDAY • Launched Twin Pack (Ocular pain & inflammation post cataract surgery, Successful clinical • Achieved #1 position in
Slide 9: BROMDAY
BROMDAY TM Convenient Once-Daily Dosing The ONLY approved once-daily Rx non-steroidal anti-inflammatory (NSAID) eye drop for pain and inflammation post-cataract surgery • BROMDAY October 2011 prescriptions equal Estimated NSAID 2011 Market Size TRx $: $367mm to highest level achieved by XIBROM • Maj
Slide 10: BROMDAY Outlook Strong
BROMDAY Outlook Strong Prescription Dollars Reflect Increasing Average Price #1 in Total Prescription Dollars (TRx$) Achieved 33% TRx$ share in only 13 months Source –IMS Health Monthly NPA All – MDs ISTA PHARMACEUTICALS 10
Slide 11: PROLENSA
PROLENSA ™ New Formula with Allowed and Patents Pending New Formula with Allowed and Patents Pending Through 2024 Key bromfenac extension for cataract-based indication • Bromfenac-based NSAID for ocular pain and inflammation associated with cataract extractionprojected – to replace BROMDAY • Positiv
Slide 12: Uncertainty Around Bromfenac Franchise Resolved
Uncertainty Around Bromfenac Franchise Resolved ISTA’s recent success with the BROMDAY conversion and with positive Phase 3 results for PROLENSA highlight the significant potential of the bromfenac franchise Questions Answers • Can ISTA successfully convert XIBROM users to Yes, ISTA successfully com
Slide 13: Bromfenac Adjunct for AMD
Bromfenac Adjunct for AMD Lower-Risk "Back of the Eye" Approach Continued expansion of successful bromfenac franchise • Higher-concentration, new formulation of bromfenac • For adjunctive treatment of age-related macular degeneration (AMD) • Paper published in Sept 2011 Issue of RETINA suggests brom
Slide 14: Proprietary Bepotastine Franchise
Proprietary Bepotastine Franchise Proven Allergy Product with Robust Opportunities A Growing Prescription Delivering Near- and Long-term Allergy Portfolio Revenue Streams BEPREVE • Continues to take share in the Lead product ophthalmic allergy market (Fast-acting eyedropsforocularitchingassociated w
Slide 15: BEPREVE
BEPREVE ® Near-term tactical drivers in place Opportunity for BEPREVE to Gain Additional Market Share • Twice-daily antihistamine eye drop to treat Estimated2011AllergyMarketSizeTRx$: $780MM itching associated with allergic conjunctivitis • 2011 revenues grew significantly • Major new managed care f
Slide 16: BEPOMAX
BEPOMAX Major Extension of Allergy Franchise Large Market Opportunity Exists 2015 Potential: $400+ million • Single agent antihistamine nasal spray • Active ingredient, bepotastine, already approved in Rx eye drop BEPREVE • For treatment of seasonal allergic rhinitis • Positive Phase 2 Study results
Slide 17: BEPOSONE
BEPOSONE ™ "Holy-Grail" Rx Nasal Allergy Product Blockbuster Market Opportunity Exists 2015 Potential: $2+ Billion • Combination patented antihistamine / steroid • Antihistamine, bepotastine, already approved in Rx eye drop BEPREVE • For treatment of seasonal allergic rhinitis (SAR) • Filed Investig
Slide 18: BEPOSONE
BEPOSONE Unique Combination and Approach • Combination of proven antihistamine and approved corticosteroid is highly desired by seasonal allergy patients and physicians alike • The market has limited expected competition from other allergic rhinitis formulations – The only late stage product current
Slide 19: Partner Potential to Unlock Additional Upside
Partner Potential to Unlock Additional Upside ISTA PHARMACEUTICALS 19
Slide 20: ISTALOL and VITRASE
ISTALOL and VITRASE Other Market-Leading products ISTALOL & VITRASE: 2011 Revenues Expected to Approach $40 Million • ISTALOL – Market-leading, once-daily beta-blocker eye drop for glaucoma – Growth through share gain and pricing – 2010 market size: ~$180 million – Patent protection to 2018 • VITRAS
Slide 21: OTC Eye Products
OTC Eye Products Expansion of Rx Business into High- Operating Margin Consumer Cash Business Existing sales force to drive practitioner-recommended sales • Over-the-Counter eye drops for treatment of dry eye and other ocular conditions • OTC product developed and tested in 2011 during prescription d
Slide 22: ISTA's OTC Tear Formula
ISTA’s OTC Tear Formula Results from Dry Eye Phase 3 Study • Successfully treatedseveredryeyedisease(DED)subjects;a first for OTC tear formulations • Reduced both sign and symptoms by approximately 30% within 7 days of treatment(twice daily) • Over50%of patientsrespondedto our OTCtear (compared to 1
Slide 23: T-Pred
T-Pred Promising Anti-Infective/Steroid Ideal supplemental product to leverage sales infrastructure • Fixed combination prednisolone & tobramycin prescription eye drop – Prednisolone by far the steroid of choice for the ophthalmic community • For steroid-responsive inflammatory ocular conditions for
Slide 24: T-PRED
T-PRED Upon Approval, New Entry to Market Long Dominated by Tobramycin /Dexamethasone Path forward determined in recent FDA meeting • Uveitisstudyshowing that the prednisolone acetate in combination is as effective as the reference product • Allergic Conjunctivitis study showing that the prednisolon
Slide 25: ISTA's Robust Near-Term Pipeline
ISTA's Robust Near-Term Pipeline Launches Drive Revenues to $500 by 2015* Formulation Phase 1 Phase 2 Phase 3 2015 Est. Candidates Market Size OTC eye products Dry eye $300 million PROLENSA Ocular Inflammation & Pain $500+ million Low-concentration bromfenac T-PRED Ocular Inflammation / Infection $1
Slide 26: ISTA's 2012 Pipeline Milestones to Drive Shareholder Value
ISTA's 2012 Pipeline Milestones to Drive Shareholder Value Product / Candidates Milestone Timing Complete stability 1H OTC tear products for dry eye Launch 2H Patent Issuance 1H PROLENSA™ File NDA 1H Approval 1H 2013 T-PRED™ Initiate Phase 3 studies 2H BEPOSONE™ Complete Phase 2 Cedar 1H Pollen Stud
Slide 27: Agenda
Agenda • ISTA’s Track Record of Success – 2011: Solid Commercial and Pipeline Progress – Attractive portfolio of highly valuable assets • ISTA’s Financial Strategy and Outlook – 2012 Guidance – Delivering Value Looking - to 2015 and Beyond • ISTA Exploring Strategic Options • Q&A ISTA PHARMACEUTICAL
Slide 28: ISTA's Overarching Financial Strategy
ISTA’s Overarching Financial Strategy • Target above industry average revenue growth • Fundgrowthfrominternallygeneratedcashflow – no financings anticipated excluding acquisitions • Utilizedisciplined investmentin R&Dat ~20%of net revenue • LeverageSG&Adownasnet revenuesgrow • Increase profitability
Slide 29: Business Development
Business Development External Value Creation Goal –To Become $1 Billion Specialty Pharmaceutical Firm • Disciplined approach to evaluation of opportunities • Rx Eye and Rx Allergy for growth and commercial synergy – Acquire marketed or soon-to-be marketed products – License late-stage products – Par
Slide 30: ISTA's 2012 Financial Guidance
ISTA’s 2012 Financial Guidance 2012 Net Revenues $180 -$195 million Gross Margin* 75% -77% R&D* 19% -22% SG&A* 45% -49% Adjusted Cash Net Income** $15 -$19 million Adjusted EBIDTA $25 -$29 million Adjusted Cash EPS** (53 mm shares) $0.28 –$0.36 per share Cash at 12/31/12*** > $100 million * %of Net
Slide 31: Mid-Term Financial Outlook
Mid-Term Financial Outlook Revenues Driven by Market Share Gains 2013 Targets BROMDAY/PROLENSA $135 –$155 million BEPREVE $100 –$120 million ISTALOL & VITRASE $ 40 –$ 50 million TOTAL NET REVENUES $275 –$325 million Adjusted Cash EPS* > $1.00 * Excludes non-cash warrant expense, non-cash interest ex
Slide 32: Delivering Value: Looking to 2015 and Beyond
Delivering Value Looking to 2015 and Beyond • "5 in 5" – 5 new product launches in next 5 years • Rx Eye, Rx Allergy, Over-the-Counter – Significantly de-risked pipeline with candidates approved previously in other indications – $500 million in revenues by 2015 • Forecasted compounded 4-year (2011 2
Slide 33: Agenda
Agenda • ISTA’s Track Record of Success – 2011: Solid Commercial and Pipeline Progress – Attractive portfolio of highly valuable assets • ISTA’s Financial Strategy and Outlook – 2012 Guidance – Delivering Value Looking - to 2015 and Beyond • ISTA Exploring Strategic Options • Q&A ISTA PHARMACEUTICAL
Slide 34: ISTA Exploring Strategic Options
ISTA Exploring Strategic Options • ISTA’s Board of Directors decided in December 2011 to explore strategic options for the company, including but not limited to: – Acquisition by or merger with another company – Acquisition of Rx or OTC business by ISTA – Partnering to reach larger audiences • Engag
Slide 35: ISTA's Recent Achievements Position the Company for Long-Term Success
ISTA's Recent Achievements Position the Company for Long-Term Success • De-risking of pipeline via positive PROLENSA Phase 3 and BEPOMAX Phase 2 trials • A more defined plan to transition the bromfenac franchise • OTC tear product formulated and successfully tested • T-PRED path forward clarified wi
Slide 36: Valeant Approach Timeline
Valeant Approach Timeline rd th Valeant first expresses Nov.23 :Valeantsendsletter Dec.12 Valeant : Dec.16th Valeant : interest in acquiring ISTA in outlining non-binding proposal to reiterates interest, makes its proposal a CEO to CEO conversation buy ISTA for $6.50 per share in cash; asks for form
Slide 37: ISTA Response
ISTA Response rd • Uponreceiptof Valeant'sproposalon November23 ,ISTAwith the help of its advisors, concluded that the proposal was grossly inadequate th – ISTArespondedto ValeantprivatelyonDecember14 reiteratingthat the offer failed to appreciate the intrinsic value of the Company • TwodayslaterVal
Slide 38: Valeant's Proposal Undervalues ISTA
Valeant’s Proposal Undervalues ISTA • Valeant’s proposal of $6.50 per share implies a multiple of 2.10x LTM revenue and 1.79x 2012E revenue • Valeant’s proposal fails to adequately compensate ISTA shareholders – It does not reflect current multiples of ISTA's peer group – It does not include a premi
Slide 39: Valeant's Bid is at a Significant Discount to Relevant Precedent Transactions
Valeant’s Bid is at a Significant Discount to Relevant Precedent Transactions • Valeant’s proposal of $6.50 per share implies a multiple of 2.10x LTM revenue • This reflects a discount of 34% and 61% to the median precedent specialty pharma and ophthalmic pharma transaction multiples, respectively •
Slide 40: ISTA is a More Attractive Company than Inspire
ISTA is a More Attractive Company than Inspire ($ in millions) ISTA Inspire Marketed 2011E LTM 3/31/11 Products Revenue Revenue • Bromfenac franchiseexclusivity - until 2013 >$90 • AzaSite® - patented until 2019 $45 • BEPREVEpatented - until 2017 >$27 • Elestat®- off-patent $16 • ISTALOLpatented - u
Slide 41: Wall Street Views on ISTA's Valuation
Wall Street Views on ISTA's Valuation Our $12.00 price target is driven by a sum-of-the-parts DCF analysis; BROMDAY at $5.00 per share; BEPREVE at $4.00 per share; ISTALOL and VITRASE at $1.00 per share; Bepotastine / pipeline at $2.00 per share with potential upside coming from SIGNIFICANT new pate
Slide 42: Wall Street Views Valeant's Proposal as Low
Wall Street Views Valeant’s Proposal as Low We believe the $6.50 offer from Valeant Pharmaceuticals is inadequate for ISTA. On the qualitative front, ISTA is the number three player in the eye prescription business behind giants Alcon and Allergan. The business is solidly positioned for profitabilit
Slide 43: ISTA's Revenue is Expected to Grow to $180+ million in 2012
ISTA’s Revenue is Expected to Grow to $180+ million in 2012 • ISTA’S revenue has grown from $83 million in 2008 to an estimated $180 – $195 million in 2012, a four year CAGR of 21.3% to 23.8% • As ISTA’s profitability grows, its adjusted EBITDA is expected to reach $25 – $29 million in 2012 Revenue
Slide 44: ISTA's Pipeline is Full of Lower Risk, New Formulations
ISTA's Pipeline is Full of Lower Risk, New Formulations of Previously Approved Drugs Product / Candidates Potential Launch Estimated Market Potential OTC Tear Product line for dry eye 2012 $300 million PROLENSA™ 2013 $500 million T-PRED™ 2014 $150 million BEPOMAX™ 2015 $400 million BEPOSONE™ 2015 $2
Slide 45: Growing Strategic Interest in Eye Care
Growing Strategic Interest in Eye Care May 2007: Jan. 2008: Sept. 2009: Dec. 2009: May 2010: Sept. 2011: Warburg Pincus Bausch and Abbott acquires Alcon acquires Valeant Santen acquires acquires Bausch Lomb acquires Visogen Inc. for Optonol for acquires Aton Novagali Pharma and Lomb for eyeonics, in
Slide 46: Conclusion
Conclusion • Valeant’s proposal to acquire ISTA at $6.50 per share is grossly inadequate – Significantly lower than ISTA’s intrinsic value – Out of line with comparable precedent transactions and peer trading multiples – Opportunistic in approach and ignores ISTA’s future prospects – Ignores benefit
Slide 47: Q&A Session
Q&A Session • Vince Anido – President and CEO • Lauren Silvernail – CFO and Vice President, Corporate Development ISTA PHARMACEUTICALS 47
Slide 48: | § TA Pharmaceuticals”
| § TA Pharmaceuticals”
Slide 49: Supplemental Information
Supplemental Information ISTA PHARMACEUTICALS 49
Slide 50: Company Timeline
Company Timeline BROMDAY™ XIBROM™ BEPREVE® ISTALOL® VITRASE® 1992 2000 2002 2004 2005 2009 2010 Acquired ISTALOL & XIBROM Revenue ISTA >$100 million Profitable* Name change to ISTA Pharmaceuticals, Inc. IPO on NASDAQ Founded as Advanced Corneal Systems * On an adjusted cash net income basis ISTA PHA
Slide 51: Bromfenac
Bromfenac 1 A Strong Track Record 2 in Meeting NSAID Goals of Cataract Surgeons • Effective anti-inflammatory activity • Rapid pain resolution • Proven safety profile • Comfortable, well- tolerated formulation Photo: Uday Devgan, MD, FACS, FRCS • Simple dosing regimen 1. NSAID = nonsteroidal anti-in
Slide 52: Unique Molecular Structure Differentiates Bromfenac
Unique Molecular Structure Differentiates Bromfenac •Competitive molecules are not halogenated –lack bromine •Addition of bromine imparts three important characteristics to the bromfenac molecule: bromfenac chemical structure – Enhances lipophilicity and facilitates penetration into ocular tissues1,
Slide 53: PROLENSA
PROLENSA Successful Development Complete • Safe and efficacious track of XIBROM and BROMDAY led to development of a lower concentration once-daily dosing of bromfenac • Formulation was modified from BROMDAY to allow more penetration of drug into ocular tissues – Concentration is decreased while effi
Slide 54: Bepotastine Besilate
Bepotastine Besilate Marketed Compound with Significant History of Safe Use More than 850 million patient uses since 2000 • Launched in Japan by Tanabe Seiyaku Co, Ltd as TALION™. • Systemic indication for allergic rhinitis, urticaria, pruritus associated with skin diseases (eczema/dermatitis, pruri
Slide 55: Bepotastine Besilate
Bepotastine Besilate Multiple Mechanisms of Action • Specific H 1 receptor antagonist – Lacks significant activity for other H1 receptors associated with potentially undesirable side effects Bzd H3 • Stabilizes mast cells M alpha 1 • Inhibits eosinophil terminal differentiation by suppressing IL-5 p
Slide 56: ISTA's Key Constituency
ISTA's Key Constituency 20,000+ US-Based Physicians • Ophthalmologists • Optometrists • Allergists Physicians write prescriptions for ISTA products that are filled by patients at drug stores, pharmacies, clinics, hospitals, government agencies, etc. ISTA PHARMACEUTICALS 56
Slide 57: Sales and Marketing Capabilities
Sales and Marketing Capabilities • ISTA has a strong, direct sales force of ~165 people calling on 20,000+ US ophthalmologists, optometrists and allergists • For the last twelve months the sales force has generated >$160 million in revenue or ~$1 million in revenue per sales territory manager • In a
Slide 58: ISTA's Key Patents and Applications
ISTA’s Key Patents and Applications PRODUCT(S) PATENT(S) AND EXPIRATION KEY CLAIM(S) BEPREVE ISSUED Bepotastine API and methods of BEPOMAX Exp: Dec 2017 , filed for extension to Sept mfg. (composition of matter for BEPOSONE 2019 Bepotastine besilate) APPLICATION Aqueous formulation Estimated Exp: Ju
Ista Pharmaceuticals — Investor Presentation (January 2012) on 6ix